Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Gains from Investment Securities: 2022-2024

Historic Gains from Investment Securities for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Dec 2024 value amounting to $19.0 million.

  • NewAmsterdam Pharma Co N.V's Gains from Investment Securities rose 1357.14% to $10.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.2 million, marking a year-over-year change of. This contributed to the annual value of $19.0 million for FY2024, which is 20.56% up from last year.
  • Per NewAmsterdam Pharma Co N.V's latest filing, its Gains from Investment Securities stood at $19.0 million for FY2024, which was up 20.56% from $15.8 million recorded in FY2023.
  • NewAmsterdam Pharma Co N.V's 5-year Gains from Investment Securities high stood at $19.0 million for FY2024, and its period low was $11.1 million during FY2022.
  • Moreover, its 3-year median value for Gains from Investment Securities was $15.8 million (2023), whereas its average is $15.3 million.
  • Data for NewAmsterdam Pharma Co N.V's Gains from Investment Securities shows a peak YoY spiked of 41.60% (in 2023) over the last 5 years.
  • Over the past 3 years, NewAmsterdam Pharma Co N.V's Gains from Investment Securities (Yearly) stood at $11.1 million in 2022, then soared by 41.60% to $15.8 million in 2023, then increased by 20.56% to $19.0 million in 2024.